aTyr Pharma (ATYR)
Develops efzofitimod and tRNA-synthetase-derived therapies for fibrosis and inflammation.
Something off on this page? Send us feedback.
Builds therapies from extracellular tRNA synthetase biology, led by efzofitimod for pulmonary sarcoidosis and systemic-sclerosis-associated ILD. The pre-commercial business centers on clinical development, with Kyorin holding Japanese rights to efzofitimod.
Uses a proprietary library of domains from all 20 tRNA synthetases to identify signaling pathways for fibrosis and inflammation therapies. Its lead program, efzofitimod, is a biologic immunomodulator being developed for pulmonary sarcoidosis and systemic-sclerosis-associated ILD.
Clinical development remains the operating focus, supported in Japan by Kyorin's licensed development and commercialization rights for efzofitimod. The organization is U.S.-based, with most full-time staff in R&D, clinical, manufacturing, and regulatory roles.
EFZO-FIT missed its primary endpoint in 2025, and further progress depends on acceptable safety and efficacy, regulatory alignment, clinical-material manufacturing, intellectual-property protection, and additional funding.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| May 20, 2026 | Freedom Broker | Upgrade | Hold | Buy | |
| Sep 16, 2025 | Wells Fargo | Downgrade | Overweight | Equal Weight | |
| Sep 16, 2025 | RBC Capital | Downgrade | Outperform | Sector Perform | |
| Sep 15, 2025 | RBC Capital | Target | $1.50 | ||
| Sep 15, 2025 | Wells Fargo | Target | $1 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $57.4M · Total debt $11.3M · Total assets $69.8M · Shareholders' equity $48.8M
- Revenue
- $0
- Operating income
- −$10.9M
- Net income
- −$10.3M
No dividends on record.
| Insiders5 holders · as of May 28, 2026 | 1.03% | 1.01M shares | |
| Strategic holders3 holders · as of Jun 5, 2026 | 22.68% | 22.24M shares | |
| Otherremainder | 76.29% | 74.83M shares |
98.09M company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Federated Hermes, Inc.Strategic | 10.75% | 10.54M | 13Gfiled Oct 7, 2025 ↗ |
FMR LLCStrategic | 6.05% | 5.94M | 13Gfiled Jun 5, 2026 ↗ |
BlackRock, Inc.Strategic | 5.88% | 5.76M | 13Gfiled Jul 17, 2025 ↗ |
Paul SchimmelInsiderdirector | 0.79% | 779,143 | Form 4filed May 28, 2026 ↗ |
Sanjay ShuklaInsiderdirector, officer: President and CEO | 0.16% | 153,553 | Form 4filed Feb 4, 2026 ↗ |
| See all 19 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 27, 2026 | Paul Schimmel | director | +100,000 | $0.4963 |
| Feb 4, 2026 | Nancy Denyes | officer: General Counsel | −1,118 | $0.9761 |
| Feb 4, 2026 | Jill Marie Broadfoot | officer: Chief Financial Officer | −1,558 | $0.9760 |
| Feb 4, 2026 | Sanjay Shukla | director, officer: President and CEO | −3,745 | $0.9760 |
| Oct 8, 2025 | Paul Schimmel | director | +682,001 | $0.8980 |
